Fulltext

A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours

Forrer, F. ; Uusijärvi, H. ; Waldherr, C. ; Cremonesi, M. ; Bernhardt, P. ; Mueller-Brand, J. ; Maecke, H.

In: European Journal of Nuclear Medicine and Molecular Imaging, 2004, vol. 31, no. 9, p. 1257-1262

Aggiungi alla tua lista
    Titre
    • A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    Auteur
    • Forrer, F.. Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    • Uusijärvi, H.. Department of Radiation Physics, Göteborg University, Gothenburg, Sweden
    • Waldherr, C.. Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    • Cremonesi, M.. Divisione di Medicina Nucleare, Istituto Europeo di Oncologia, Milan, Italy
    • Bernhardt, P.. Department of Radiation Physics, Göteborg University, Gothenburg, Sweden
    • Mueller-Brand, J.. Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    • Maecke, H.. Division of Radiological Chemistry, University Hospital, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • European Journal of Nuclear Medicine and Molecular Imaging, 2004, vol. 31, no. 9, p. 1257-1262. Springer-Verlag; http://www.springer.de
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:312853
    Summary
    [Yttrium-90-DOTA-Tyr3]-octreotide (DOTATOC) and [177Lu-DOTA-Tyr3-Thr8]-octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy (PRMRT) in neuroendocrine tumours. No human data comparing these two compounds are available so far. We used 111In as a surrogate for 90Y and 177Lu and examined whether one of the 111In-labelled peptides had a more favourable biodistribution in patients with neuroendocrine tumours. Special emphasis was given to kidney uptake and tumour-to-kidney ratio since kidney toxicity is usually the dose-limiting factor. Five patients with metastatic neuroendocrine tumours were injected with 222MBq 111In-DOTATOC and 111In-DOTATATE within 2 weeks. Up to 48h after injection, whole-body scans were performed and blood and urine samples were collected. The mean absorbed dose was calculated for tumours, kidney, liver, spleen and bone marrow. In all cases 111In-DOTATATE showed a higher uptake (%IA) in kidney and liver. The amount of 111In-DOTATOC excreted into the urine was significantly higher than for 111In-DOTATATE. The mean absorbed dose to the red marrow was nearly identical. 111In-DOTATOC showed a higher tumour-to-kidney absorbed dose ratio in seven of nine evaluated tumours. The variability of the tumour-to-kidney ratio was high and the significance level in favour of 111In-DOTATOC was P=0.065. In five patients the pharmacokinetics of 111In-DOTATOC and 111In-DOTATATE was found to be comparable. The two peptides appear to be nearly equivalent for PRMRT in neuroendocrine tumours, with minor advantages for 111In/90Y-DOTATOC; on this basis, we shall continue to use 90Y-DOTATOC for PRMRT in patients with metastatic neuroendocrine tumours